CINCINNATIIn a review of nationwide hospital databases, University of Cincinnati (UC) emergency medicine and neurology researchers have found that the rate of treatment with the standard therapy for acute ischemic stroke patients has doubled since 2005.
Their paper, "Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States," is published online ahead of print in the journal Stroke. The study estimates between 23,800 and 36,000 U.S. patients received rtPA treatment in 2009up from between 10,800 to 12,600 in 2004.
Since its approval by the Food and Drug Administration in 1996, recombinant tissue-type plasminogen activator (rtPA) remains the only FDA-approved therapy for treatment of acute ischemic stroke (AIS), caused by blocked blood flow in the brain. The clot-busting drug can decrease the likelihood of disability in stroke patients, but only when administrated intravenously within hours of the stroke.
However, treatment rates of rtPA remain relatively low, says lead author and UC assistant professor of emergency medicine and neurosurgery Opeolu Adeoye, MD, mainly because many patients do not arrive to the hospital in time to receive the drug. There are also a number of exclusions for rtPA, based on bleeding risks, recent surgery and other factors.
Previous UC research using the Medicare Provider and Analysis Review and a privately maintained hospital database concluded that, from 2001-2004, between 1.8 percent and 2.1 percent of AIS patients received the thrombolytic drug. Using data from the same databases, Adeoye and colleagues sought to update those figures in this new study. Their results show a significant jumpin 2009, 3.4 percent to 5.2 percent of AIS patients in the U.S. received rtPA, approximately double the rate of treatment in 2005.
Adeoye writes that the jump is "strikingly different" from the previous study, which documented essentially no rise in rtPA treatment
|Contact: Katy Cosse|
University of Cincinnati Academic Health Center